Aura Biosciences, Inc. (NASDAQ:AURA) Shares Sold by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC cut its holdings in Aura Biosciences, Inc. (NASDAQ:AURA) by 34.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,297 shares of the company’s stock after selling 2,307 shares during the period. Tower Research Capital LLC TRC’s holdings in Aura Biosciences were worth $38,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in AURA. SG Americas Securities LLC acquired a new position in Aura Biosciences in the third quarter valued at approximately $113,000. TD Asset Management Inc lifted its holdings in Aura Biosciences by 100.0% in the third quarter. TD Asset Management Inc now owns 107,912 shares of the company’s stock valued at $968,000 after acquiring an additional 53,956 shares during the last quarter. Levin Capital Strategies L.P. lifted its holdings in Aura Biosciences by 15.9% in the third quarter. Levin Capital Strategies L.P. now owns 81,095 shares of the company’s stock valued at $727,000 after acquiring an additional 11,095 shares during the last quarter. Eventide Asset Management LLC raised its position in Aura Biosciences by 3.0% in the third quarter. Eventide Asset Management LLC now owns 3,024,905 shares of the company’s stock valued at $27,133,000 after purchasing an additional 89,386 shares during the period. Finally, Adage Capital Partners GP L.L.C. raised its position in Aura Biosciences by 6.1% in the third quarter. Adage Capital Partners GP L.L.C. now owns 2,875,000 shares of the company’s stock valued at $25,789,000 after purchasing an additional 165,000 shares during the period. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Stock Up 1.6 %

NASDAQ AURA traded up $0.12 on Thursday, reaching $7.77. The stock had a trading volume of 127,562 shares, compared to its average volume of 165,306. Aura Biosciences, Inc. has a 12-month low of $5.99 and a 12-month high of $13.50. The stock has a fifty day moving average price of $7.87 and a two-hundred day moving average price of $8.20.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Wednesday, March 27th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.11). Research analysts predict that Aura Biosciences, Inc. will post -2.02 EPS for the current year.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.